A method of preparing a mouse model of herpes using a herpes simplex virus and hydrocortisone, and a mouse model of herpes prepared the method are disclosed. When the preparation method is used, an animal model in which the symptoms of herpes clearly appear can be prepared, and thus the animal model can be widely used in the development of therapeutic agents for herpes simplex virus infection. A use of the mouse model in screening and developing a candidate therapeutic agent is also disclosed.

The invention describes a method to identify and stage human herpesvirus-mediated neurodegenerations by measuring secreted herpesvirus protein and RNA levels in a blood sample and comparing that level to an individual's baseline or reference level. Combining herpesvirus secretome levels with other neurodegeneration biomarkers, such as coagulation factors and cell adhesion molecules, can aid in diagnosis and staging of neuropathology. Sensitive and economical ELISA diagnostic kits can detect and quantify the herpesvirus secretome and neurodegeneration biomarkers to diagnose herpesvirus-mediated neurodegeneration, stage disease, and predict disease progression. Finally, this method will elucidate herpesvirus-mediated neurodegenerations and aid in developing therapeutics.

Methods for obtaining a sample from a subject include providing a sample collection room within a retail store; and obtaining a sample from a subject at a retail location. Sample collection rooms may house a sample analysis device or system. Samples may be small, e.g., a finger-stick capillary blood sample.

Provided are devices for assessing the presence of SARS-CoV-2 in a biological sample, the devices comprising a substrate comprising a top surface and a back surface; and, an electrode on the top surface of the substrate, wherein the electrode is functionalized with a detection moiety that binds SARS-CoV-2 spike protein. Also disclosed are articles that include such devices, and methods for assessing the presence of SARS-CoV-2 in a biological sample using the disclosed devices. The present disclosure also provides devices for assessing the presence of herpes simplex virus (HSV) in a biological sample comprising a substrate that includes a top surface and a back surface; and, an electrode on the top surface of the substrate, wherein the electrode is functionalized with a detection moiety that binds HSV glycoprotein gD2, such as nectin-1. Also disclosed are articles that include such devices, and methods for assessing the presence of HSV in a biological sample using the disclosed devices.

Provided herein are methods of determining binding kinetics of a ligand. In some embodiments, the methods include contacting the ligand with a first surface of a substrate, which first surface comprises an electrically conductive coating and a population of virions connected to the first surface via one or more linker moieties, wherein viral envelopes of the virions display one or more proteins that bind, or are capable of binding, to the ligand, applying an alternating current electric field to the substrate to induce the virions to oscillate proximal to the first surface of the substrate, and detecting changes in oscillation amplitudes of the virions over a duration. Related virion oscillator array devices, systems and computer readable media are also provided.

The present invention refers to a new monoclonal antibody or fragment thereof, called 11B2C7, which specifically recognizes herpes simplex virus (HSV), in its two types, herpes simplex virus type 1 and herpes simplex virus type 2 (HSV-1 and HSV-2). Preferably, the antibody of the invention is useful for the development of methods for the diagnosis of herpes simplex virus infection, as well as for the production of pharmaceutical compositions intended for the treatment, protection and/or prophylaxis of infection specifically caused by HSV-1 and HSV-2.

The present invention refers to a new monoclonal antibody or fragment thereof, called 14F5F6, which specifically recognizes herpes simplex virus (HSV), in its two types, herpes simplex virus type 1 and herpes simplex virus type 2 (HSV-1 and HSV-2). Preferably, the antibody of the invention is useful for the development of methods for the diagnosis of herpes simplex virus infection, as well as for the production of pharmaceutical compositions intended for the treatment, protection and/or prophylaxis of infection specifically caused by HSV-1 and HSV-2.

The present invention relates to antigen binding protein, and in particular monoclonal antibodies, with bind to a HSV gEgI heterodimer, and to the use of such in detection and potency assays and in therapy.

Methods for obtaining a sample from a subject include providing a sample collection room within a retail store; and obtaining a sample from a subject at a retail location. Sample collection rooms may house a sample analysis device or system. Samples may be small, e.g., a finger-stick capillary blood sample.

Described herein is a newly found outer membrane protein gene specific for Helicobacter suis and a gene product thereof. Also described herein is a method for determining infection of a subject with Helicobacter suis and a method for treatment using an antibody against the gene product.